IAMA-005 / Nanjing JSIAMA Biopharma - LARVOL DELTA

Pre-clinical development of IAMA-004, a tri-specific antibody targeting innate immune receptors and tumor targets (AACR 2024) - "In all of these ADCC experiments, IAMA-004 showed superior tumor cell killing activities to those mediated by DS-8201 or Trastuzmab. When combined with IAMA-005 (a Fc-IL2-IFN-α fusion cytokine), the tumor cell killing activities were dramatically increased. In addition, IAMA-004 was also tested in patient-derived Ex-Vivo fluids (one malignant pleural effusion and one malignant asities) and demonstrated tumor cell killing efficacies; and the killing activity could be attributed to the specific arms of the molecule. These results suggest that it is feasible to combine more than one innate engager in one molecule to carry out specific functions in the heterogeneous immune status for the treatment of advanced cancer patients."

Preclinical • Trispecific • Oncology • FCGR3A • IFNA1 • IL2 • TNFRSF8

Pre-clinical development of IAMA-005, a long-acting cytokine fusion of modified IL-2 and IFN-α (AACR 2024) - "When combined with IAMA-004 (a Her2-CD47-CD16 tri-specific antibody) in vitro, the tumor cell killing activities were dramatically increased. The in vivo assays to demonstrate efficacy and safety are ongoing and will be presented in the poster. These results suggest that this fusion cytokine molecule may be used in monotherapy in certain indications and an excellent complementary therapeutic to antibody targeted therapies or immunotherapies when used in combination."

IO biomarker • Preclinical • Genito-urinary Cancer • Hairy Cell Leukemia • Hematological Malignancies • Leukemia • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8 • HER-2 • IFNA1 • IL2

Heterogeneity of immune status in patient-derived malignant pleural effusion and ascites: Relationship to the ex-vivo efficacy of a HER2-targeted tri-specific antibody and a novel cytokine fusion protein. (ASCO 2024) - "IAMA-004 and IAMA-005 enhanced the killing of Her2 positive tumor cells by ~30% and ~40% respectively; Herceptin plus TTI-622 was not able to enhance the tumor cell killing. In combination with nivolumab, IAMA-004 was able to enhance the Granzyme B and IFN-γ secretion significantly without enhancing the tumor cell killing... Immune status from MPE or MA are heterogenous in both adaptive and innate immunity. Using combinations of innate immune targeting therapeutics and adaptive immune check point inhibitors may be able to correct the specific deficiency with precision and effectively treat these diseases."

Heterogeneity • Pleural effusion • Preclinical • Trispecific • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Ovarian Cancer • Respiratory Diseases • Solid Tumor • CD4 • CD8 • GZMB • HER-2 • IFNG